Neurofibromatosis 2011

A report of the Children's Tumor Foundation Annual Meeting

Michel Kalamarides, Maria T. Acosta, Dusica Babovic-Vuksanovic, Olli Carpen, Karen Cichowski, D. Gareth Evans, Filippo Giancotti, C. Oliver Hanemann, David Ingram, Alison C. Lloyd, Debra A. Mayes, Ludwine Messiaen, Helen Morrison, Kathryn North, Roger Packer, Duojia Pan, Anat Stemmer-Rachamimov, Meena Upadhyaya, David Viskochil, Margret R. Wallace & 2 others Kim Hunter-Schaedle, Nancy Ratner

Research output: Contribution to journalArticle

Abstract

The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.

Original languageEnglish (US)
Pages (from-to)369-380
Number of pages12
JournalActa Neuropathologica
Volume123
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Neurofibromatoses
Neoplasms
Research
Optic Nerve Glioma
Morbidity
Ependymoma
Neurofibroma
Mutation
Meningioma
Clinical Trials
Therapeutics
Pharmaceutical Preparations
Genes
Schwannomatosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Kalamarides, M., Acosta, M. T., Babovic-Vuksanovic, D., Carpen, O., Cichowski, K., Gareth Evans, D., ... Ratner, N. (2012). Neurofibromatosis 2011: A report of the Children's Tumor Foundation Annual Meeting. Acta Neuropathologica, 123(3), 369-380. https://doi.org/10.1007/s00401-011-0905-0

Neurofibromatosis 2011 : A report of the Children's Tumor Foundation Annual Meeting. / Kalamarides, Michel; Acosta, Maria T.; Babovic-Vuksanovic, Dusica; Carpen, Olli; Cichowski, Karen; Gareth Evans, D.; Giancotti, Filippo; Oliver Hanemann, C.; Ingram, David; Lloyd, Alison C.; Mayes, Debra A.; Messiaen, Ludwine; Morrison, Helen; North, Kathryn; Packer, Roger; Pan, Duojia; Stemmer-Rachamimov, Anat; Upadhyaya, Meena; Viskochil, David; Wallace, Margret R.; Hunter-Schaedle, Kim; Ratner, Nancy.

In: Acta Neuropathologica, Vol. 123, No. 3, 03.2012, p. 369-380.

Research output: Contribution to journalArticle

Kalamarides, M, Acosta, MT, Babovic-Vuksanovic, D, Carpen, O, Cichowski, K, Gareth Evans, D, Giancotti, F, Oliver Hanemann, C, Ingram, D, Lloyd, AC, Mayes, DA, Messiaen, L, Morrison, H, North, K, Packer, R, Pan, D, Stemmer-Rachamimov, A, Upadhyaya, M, Viskochil, D, Wallace, MR, Hunter-Schaedle, K & Ratner, N 2012, 'Neurofibromatosis 2011: A report of the Children's Tumor Foundation Annual Meeting', Acta Neuropathologica, vol. 123, no. 3, pp. 369-380. https://doi.org/10.1007/s00401-011-0905-0
Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Gareth Evans D et al. Neurofibromatosis 2011: A report of the Children's Tumor Foundation Annual Meeting. Acta Neuropathologica. 2012 Mar;123(3):369-380. https://doi.org/10.1007/s00401-011-0905-0
Kalamarides, Michel ; Acosta, Maria T. ; Babovic-Vuksanovic, Dusica ; Carpen, Olli ; Cichowski, Karen ; Gareth Evans, D. ; Giancotti, Filippo ; Oliver Hanemann, C. ; Ingram, David ; Lloyd, Alison C. ; Mayes, Debra A. ; Messiaen, Ludwine ; Morrison, Helen ; North, Kathryn ; Packer, Roger ; Pan, Duojia ; Stemmer-Rachamimov, Anat ; Upadhyaya, Meena ; Viskochil, David ; Wallace, Margret R. ; Hunter-Schaedle, Kim ; Ratner, Nancy. / Neurofibromatosis 2011 : A report of the Children's Tumor Foundation Annual Meeting. In: Acta Neuropathologica. 2012 ; Vol. 123, No. 3. pp. 369-380.
@article{87f43a73ff4d456b8b77f0a43c47f583,
title = "Neurofibromatosis 2011: A report of the Children's Tumor Foundation Annual Meeting",
abstract = "The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.",
author = "Michel Kalamarides and Acosta, {Maria T.} and Dusica Babovic-Vuksanovic and Olli Carpen and Karen Cichowski and {Gareth Evans}, D. and Filippo Giancotti and {Oliver Hanemann}, C. and David Ingram and Lloyd, {Alison C.} and Mayes, {Debra A.} and Ludwine Messiaen and Helen Morrison and Kathryn North and Roger Packer and Duojia Pan and Anat Stemmer-Rachamimov and Meena Upadhyaya and David Viskochil and Wallace, {Margret R.} and Kim Hunter-Schaedle and Nancy Ratner",
year = "2012",
month = "3",
doi = "10.1007/s00401-011-0905-0",
language = "English (US)",
volume = "123",
pages = "369--380",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Neurofibromatosis 2011

T2 - A report of the Children's Tumor Foundation Annual Meeting

AU - Kalamarides, Michel

AU - Acosta, Maria T.

AU - Babovic-Vuksanovic, Dusica

AU - Carpen, Olli

AU - Cichowski, Karen

AU - Gareth Evans, D.

AU - Giancotti, Filippo

AU - Oliver Hanemann, C.

AU - Ingram, David

AU - Lloyd, Alison C.

AU - Mayes, Debra A.

AU - Messiaen, Ludwine

AU - Morrison, Helen

AU - North, Kathryn

AU - Packer, Roger

AU - Pan, Duojia

AU - Stemmer-Rachamimov, Anat

AU - Upadhyaya, Meena

AU - Viskochil, David

AU - Wallace, Margret R.

AU - Hunter-Schaedle, Kim

AU - Ratner, Nancy

PY - 2012/3

Y1 - 2012/3

N2 - The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.

AB - The 2011 annual meeting of the Children's Tumor Foundation, the annual gathering of the neurofibromatosis (NF) research and clinical communities, was attended by 330 participants who discussed integration of new signaling pathways into NF research, the appreciation for NF mutations in sporadic cancers, and an expanding pre-clinical and clinical agenda. NF1, NF2, and schwannomatosis collectively affect approximately 100,000 persons in US, and result from mutations in different genes. Benign tumors of NF1 (neurofibroma and optic pathway glioma) and NF2 (schwannoma, ependymoma, and meningioma) and schwannomatosis (schwannoma) can cause significant morbidity, and there are no proven drug treatments for any form of NF. Each disorder is associated with additional manifestations causing morbidity. The research presentations described in this review covered basic science, preclinical testing, and results from clinical trials, and demonstrate the remarkable strides being taken toward understanding of and progress toward treatments for these disorders based on the close interaction among scientists and clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84857917804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857917804&partnerID=8YFLogxK

U2 - 10.1007/s00401-011-0905-0

DO - 10.1007/s00401-011-0905-0

M3 - Article

VL - 123

SP - 369

EP - 380

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 3

ER -